Production of aluminum based adjuvants
Ended Awarded Last action
- Contract number
- HHSN27200003
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,048
Award facts
- Opportunity
-
- NIHAI2015035 Solicitation number
- Contract value 1% obligated
-
- $2,102,618.00 Current, with exercised options
- $2,857,893.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Funding Only Action | $18,048 | |
| Funding Only Action | $207,588 | |
| Definitize Change Order | $79,667 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $10,168 | |
| Change Order | $34,947 | |
| Definitize Change Order | $0 | |
| Original award | $1,752,200 |
Show all 11
About this award
Advanced Bioscience Laboratories, Inc. (ABL) was awarded a delivery order contract by the National Institute of Allergy and Infectious Diseases (NIAID) on September 20, 2017, for the production of aluminum-based adjuvants to support NIAID's preclinical development initiatives. This cost-plus-fixed-fee contract, with no set-aside designation, carries a ceiling value of $2.86 million and is scheduled for completion by December 31, 2026. The work will be performed at ABL's facility in Potomac, Maryland. This delivery order falls under ABL's broader Indefinite Delivery Vehicle with NIAID for Resources to Advance Pediatrics and HIV Prevention Science, valued at $98.9 million, which supports a comprehensive range of preclinical development services.
ABL is a leading contract research and manufacturing organization specializing in biologics development, including vaccines and immunotherapies, with extensive experience supporting infectious disease research for federal agencies. The company's expertise in manufacturing aluminum-based adjuvants—critical components in vaccine formulations that enhance immune response—aligns with NIAID's mission to develop medical countermeasures for infectious diseases. Through this engagement and its other significant IDVs with federal health institutes, ABL demonstrates its established capabilities in cGMP manufacturing, analytical testing, and quality assurance services supporting the development of vaccines and therapeutics across multiple disease areas.
Quick answers
Who was awarded contract HHSN27200003?
HHSN27200003 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 20, 2017.
How much is contract HHSN27200003 worth?
The government has obligated $18,048 on HHSN27200003. Its current value, with exercised options, is $2,102,618. Its potential value, with all options, is $2,857,893.
Is contract HHSN27200003 an order under another contract?
Yes. HHSN27200003 is a delivery order under HHSN272201700010I, an indefinite delivery contract.
Was contract HHSN27200003 competed?
The extent of competition for HHSN27200003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award